

**Table 2:** Comparison of maternal serum PLGF, sFLT-1, sFLT-1/PLGF ratio, endothelin, IL-6, TNF- $\alpha$  and VCAM between normotensive controls, the total cohort of women with CH and groups 1-4.

Clinical feature	Controls (n=142)	All CH (n=650)	Group 1 (n=81)	Group 2 (n=199)	Group 3 (n=221)	Group 4 (n=149)
<b>Angiogenic factors</b>						
PLGF MoM, median (IQR)	1.02 (0.79-1.27)	0.86 (0.61-1.19)***	0.86 (0.55-1.31)	0.81 (0.60-1.18)	0.87 (0.62-1.17)	0.87 (0.62-1.19)*
sFLT-1 MoM, median (IQR)	0.98 (0.79-1.27)	0.84 (0.59-1.18)***	0.88 (0.61-1.22)	0.82 (0.59-1.14)**	0.77 (0.54-1.19)***	0.94 (0.66-1.21)
sFLT-1/PLGF ratio MoM, median (IQR)	1.02 (0.71-1.40)	1.10 (0.76-1.67)	1.17 (1.40-1.80)	1.10 (0.76-1.63)	1.09 (0.72-1.69)	1.10 (0.83-1.73)
<b>Inflammatory mediators</b>						
Endothelin MoM, median (IQR)	1.00 (0.82-1.22)	1.08 (0.89-1.34)**	1.16 (0.92-1.43)*	1.07 (0.85-1.30)**	1.06 (0.84-1.32)*	1.13 (0.94-1.35)*
IL-6 MoM, median (IQR)	0.98 (0.73-1.29)	0.85 (0.60-1.18)***	0.86 (0.56-1.30)	0.84 (0.61-1.17)	0.85 (0.63-1.23)	0.86 (0.59-1.12)*
TNF- $\alpha$ , median (IQR)	1.95 (1.70-2.24)	1.98 (1.69-2.38)	2.06 (1.78-2.64)	1.982 (1.66-2.30)	1.97 (1.69-2.43)	1.92 (1.75-2.44)
VCAM MoM, median (IQR)	1.00 (0.87-1.1)	0.97 (0.83-1.14)	1.00 (0.88-1.14)	0.952 (0.83-1.11)	0.96 (0.79-1.16)	0.98 (0.82-1.14)

\*: statistically significant compared to controls,  $p < 0.05$ , \*\*:  $p < 0.01$ , \*\*\*:  $p < 0.001$